Results 231 to 240 of about 41,661 (291)

Association between polygenic risk scores and cardiovascular events in prostate cancer patients receiving androgen deprivation therapy in Han Chinese. [PDF]

Cardiooncology
Nian QY, Chang LW, Yang HW, Li JR, Hung SC, Chen IC.   +5 more
europepmc   +1 more source

Rezvilutamide in combination with androgen deprivation therapy (ADT) with or without docetaxel in the neoadjuvant treatment of oligometastatic prostate cancer (REDOOM): study protocol for an open-label, parallel-cohort, multicentre clinical study. [PDF]

BMJ Open
Chen ZJ, Zhu XX, Huang H, Ding YZ, Zhuang YD, Wang L, Li P, Yu KY, Chen HD, Wang HL, Li HY, Cai B, Deng ZX, Pan Y, Yang Y, Li P, Huang KT, Ji XW, Lin Q, Chen W.   +19 more
europepmc   +1 more source

Analysis of treatment options and survival outcomes for patients with localized prostate cancer: a focus on androgen deprivation therapy. [PDF]

Front Oncol
Li Z, Sun S, Tan C, Yan H, Zhang Y, Yang Y, Xiong G.   +6 more
europepmc   +1 more source

Polygenic Risk Score as a Predictor of Bone Fracture or Osteoporosis in Prostate Cancer Patients Receiving Androgen Deprivation Therapy. [PDF]

Cancer Med
Liu YQ, Chang LW, Yang HW, Li JR, Chen YM, Hung SC, Chen IC.   +6 more
europepmc   +1 more source

Preferences between three options for androgen deprivation therapy: a focus group study. [PDF]

BJU Int
Rush HL, Merrick S, Marshall J, Deighan J, Abdel-Aty H, Alhasso A, Clarke NW, Kockelbergh R, Mangar S, Rosen SD, James ND, Gilbert DC, South A, Langley RE.   +13 more
europepmc   +1 more source

Indirect treatment comparisons of darolutamide plus docetaxel and androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer. [PDF]

Sci Rep
Wang H, Fawsitt CG, Orishaba P, Thom H, Paracha N, Xue R, Zhang Y, Xing N.   +7 more
europepmc   +1 more source

Androgen Deprivation Therapy–Induced Cardiovascular Disease

Journal of Global Oncology, 2016
openaire   +2 more sources

Long-Term Follow-Up of Neoadjuvant Enzalutamide Plus Androgen Deprivation Therapy in Localized Prostate Cancer: A Secondary Analysis of a Neoadjuvant Feasibility Trial. [PDF]

Prostate
Millan B, Pramod N, Blachman-Braun R, Saini J, Loebach L, Patel M, Gurram S, Turkbey B, Karzai F, Pinto PA.   +9 more
europepmc   +1 more source

Integrating deep learning with multimodal MRI habitat radiomics: toward personalized prediction of risk stratification and androgen deprivation therapy outcomes in prostate cancer. [PDF]

Insights Imaging
Zhang YF, Zhou C, Wang J, He H, Yang J, Zhang W, Hu H, Wang Q, He W, Wang C, Wang R, Zhao L, Zhou F.   +12 more
europepmc   +1 more source

Cognitive Impairment in Prostate Cancer Patients Receiving Androgen Deprivation Therapy: A Scoping Review. [PDF]

Cancers (Basel)
Barreira JV, Barreira P, Falcão G, Garcez D, Silva P, Santos G, Fontes-Sousa M, Leão Mendes J, Reis F, Santos CF, Ribeiro F, Capelas ML.   +11 more
europepmc   +1 more source